Meeder Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Meeder Asset Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,628	Closed	-$87K	–	1199
2021 Q3	$87K	Buy	2,628 +952	+57%	+$53.5K	﹤0.01%	935
2021 Q2	$106K	Sell	1,676 -2,531	-60%	-$131K	﹤0.01%	891
2021 Q1	$180K	Buy	+4,207	New	+$199K	0.01%	753
2020 Q3	–	Sell	-4,693	Closed	-$153K	–	2157
2020 Q2	$153K	Buy	4,693 +2,725	+138%	+$87.5K	0.01%	655
2020 Q1	$53K	Sell	1,968 -1,687	-46%	-$59.9K	﹤0.01%	890
2019 Q4	$112K	Buy	3,655 +3,360	+1,139%	+$93K	0.01%	759
2019 Q3	$7K	Sell	295 -155	-34%	-$4.27K	﹤0.01%	1631
2019 Q2	$11K	Hold	450	–	–	﹤0.01%	1419
2019 Q1	$9K	Buy	450 +11	+3%	+$173	﹤0.01%	1258
2018 Q4	$5K	Buy	+439	New	+$6.74K	﹤0.01%	1397
2018 Q3	–	Sell	-133	Closed	-$2.93K	–	1530
2018 Q2	$2.93K	Buy	+133	New	+$3.06K	﹤0.01%	1361

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Meeder Asset Management's APLS Position: Q4 2021 in Review

Meeder Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q4 2021, closing a stake of 2,628 shares — an estimated $87K sold.

Meeder Asset Management first reported a position in APLS in Q2 2018 and held it in 11 quarters. The position peaked at $180K in Q1 2021. 186 funds tracked by Wall St. Rank hold APLS as of Q4 2021.

Meeder Asset Management reported no remaining Apellis Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Meeder Asset Management sold 2,628 Apellis Pharmaceuticals shares in Q4 2021, an estimated $87K.
Meeder Asset Management first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 11 quarters.
Meeder Asset Management's Apellis Pharmaceuticals position peaked at $180K in Q1 2021.
186 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.